The global respiratory inhaler devices market is on the cusp of significant transformation over the next decade, driven by a rising incidence of respiratory diseases, technological advancements, and ...

The FDA is poised to issue a final decision on the approval and marketing of Yutrepia, an inhaled dry powder formulation of ...

Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that the U.S. Food and Drug ...

Italian biopharma Chiesi Group has announced a major investment in Nerviano, near Milan, with the building of a new facility ...

Italy's Chiesi Group has revealed plans to spend €430 million ($464 million) on a new therapeutics manufacturing facility at ...

A shuttered Milanese manufacturing site with a storied history is getting a new lease on life, thanks to a nearly ...